Modulation of the gut microbiome by postbiotic therapy in Rett syndrome
16S rRNA gene sequencing of the fecal microbiota of 28 participants randomized to BizetaFlox, a formulation composed by the postbiotic sodium butyrate and ZnO (Bz, n=13) or Lalbaay, a formulation composed by sodium butyrate and the prebiotics inulin, FOS and a-lactalbumin (Lb, n=15) at baseline (T0), end-of-treatment (T1, week 12) and follow-up visit (T2, week 16). Fecal samples were collected, aliquoted and stored at -80°C until DNA extraction. DNA extraction, 16S rRNA gene amplification, purification, library preparation and pair-end sequencing on the Illumina MiSeq platform were performed as previously described (Burrello et al, 2022)
16S rRNA gene sequencing of the fecal microbiota of 28 participants randomized to BizetaFlox, a formulation composed by the postbiotic sodium butyrate and ZnO (Bz, n=13) or Lalbaay, a formulation composed by sodium butyrate and the prebiotics inulin, FOS and a-lactalbumin (Lb, n=15) at baseline (T0), end-of-treatment (T1, week 12) and follow-up visit (T2, week 16). Fecal samples were collected, aliquoted and stored at -80°C until DNA extraction. DNA extraction, 16S rRNA gene amplification, purification, library preparation and pair-end sequencing on the Illumina MiSeq platform were performed as previously described (Burrello et al, 2022)